Eight important updates for National Prostate Cancer Awareness Month

National Prostate Cancer Awareness Month is observed every September.

Health care providers and advocates use the campaign to educate men about the importance of prostate health, as well as the risk factors for and symptoms of prostate cancer.

In conjunction with this observation, HemOnc Today and Healio present eight important updates in prostate cancer research and treatment.

1. Stereotactic ablative radiation appeared to be an effective and safe treatment for men with oligometastatic prostate cancer, with significant benefits observed in terms of 6-month freedom from progression and PFS. Read more.

2. The FDA expanded the approval of apalutamide (Erleada, Janssen) to include treatment of men with metastatic castration-sensitive prostate cancer. Apalutamide — an oral androgen receptor inhibitor — already had been approved for the treatment of nonmetastatic castration-resistant prostate cancer. Read more.

3. Long-term antiandrogen therapy did not improve OS when administered during early salvage radiation therapy among patients with recurrent prostate cancer and low PSA scores. Read more.

4. A health facility’s annual caseload appeared to influence OS for men with prostate cancer who underwent radical prostatectomy. Read more.

5. Abiraterone acetate (Zytiga, Janssen) and enzalutamide (Xtandi; Astellas, Pfizer) appeared to increase the risk for death among older men with advanced prostate cancer and pre-existing cardiovascular conditions. Read more.

6. Elderly men with prostate cancer appeared more likely to be diagnosed with Alzheimer’s disease or dementia if treated with androgen deprivation therapy. Read more.

7. Men with prostate cancer who underwent radical prostatectomy remained interested in sex despite functional losses and appeared able to salvage satisfaction. Read more.

8. Routine comprehensive genomic profiling identified genomic alterations that are under investigation as biomarkers for targeted therapies in more than half of tumor samples from nearly 3,500 men with prostate cancer. Read more.

National Prostate Cancer Awareness Month is observed every September.

Health care providers and advocates use the campaign to educate men about the importance of prostate health, as well as the risk factors for and symptoms of prostate cancer.

In conjunction with this observation, HemOnc Today and Healio present eight important updates in prostate cancer research and treatment.

1. Stereotactic ablative radiation appeared to be an effective and safe treatment for men with oligometastatic prostate cancer, with significant benefits observed in terms of 6-month freedom from progression and PFS. Read more.

2. The FDA expanded the approval of apalutamide (Erleada, Janssen) to include treatment of men with metastatic castration-sensitive prostate cancer. Apalutamide — an oral androgen receptor inhibitor — already had been approved for the treatment of nonmetastatic castration-resistant prostate cancer. Read more.

3. Long-term antiandrogen therapy did not improve OS when administered during early salvage radiation therapy among patients with recurrent prostate cancer and low PSA scores. Read more.

4. A health facility’s annual caseload appeared to influence OS for men with prostate cancer who underwent radical prostatectomy. Read more.

5. Abiraterone acetate (Zytiga, Janssen) and enzalutamide (Xtandi; Astellas, Pfizer) appeared to increase the risk for death among older men with advanced prostate cancer and pre-existing cardiovascular conditions. Read more.

6. Elderly men with prostate cancer appeared more likely to be diagnosed with Alzheimer’s disease or dementia if treated with androgen deprivation therapy. Read more.

7. Men with prostate cancer who underwent radical prostatectomy remained interested in sex despite functional losses and appeared able to salvage satisfaction. Read more.

8. Routine comprehensive genomic profiling identified genomic alterations that are under investigation as biomarkers for targeted therapies in more than half of tumor samples from nearly 3,500 men with prostate cancer. Read more.